Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23234695 | 0.80 | FFAR2 (0.31) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL21543198 | 0.80 | SLC16A3 (0.32) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2598798 | 0.75 | LTA4H (0.41) | SMYD2HTTSMN1; SMN2 | |
| SCHEMBL21639770 | 0.74 | AOC1 (0.45) | — | |
| SCHEMBL21543547 | 0.74 | IDO1 (0.38) | HTT | |
| SCHEMBL4298877 | 0.71 | NOS3 (0.45) | SMYD2 | |
| SCHEMBL4821504 | 0.71 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3598198 | 0.70 | ALOX5AP (0.41) | SMYD2CYP3A4HTTSMN1; SMN2DHFR | |
| SCHEMBL23272953 | 0.70 | DUT (0.30) | — | |
| SCHEMBL29823172 | 0.70 | DUT (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583854-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4268898-A2 | KRAS G12C INHIBITORS FOR TREATING CANCER | Amgen Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220002298-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-01-06 | — | — | US | disclosed |
| EP-3807276-A2 | KRAS G12C INHIBITORS ENCOMPASSING A PIPERAZINE RING AND USE THEREOF IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3802537-A1 | KRAS G12C INHIBITORS FOR TREATING CANCER | Amgen Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | SMYD2 1861/4885POLB 596/4885CYP3A4 4426/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | SMYD2 1861/4885POLB 596/4885CYP3A4 4426/4885 |
| US-12583854-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, APC | SMYD2 684/4885POLB 2374/4885CYP3A4 4767/4885 |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMYD2 1431/4885POLB 632/4885CYP3A4 4763/4885 |
| US-20220002298-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMYD2 1431/4885POLB 632/4885CYP3A4 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.